COVID-19 Diagnostics Market to Reach USD 32.7 Billion by 2034

as Molecular Testing, Point-of-Care Kits, and Pandemic-Readiness Strategies Expand - Key Players Include Roche, Abbott, and Thermo Fisher Scientific
Pune, India, November 11, 2025 - The global COVID-19 Diagnostics Market is projected to grow from USD 21.5 billion in 2024 to USD 32.7 billion by 2034, registering a CAGR of 4.2 %, according to Exactitude Consultancy. While global infection rates have declined, continued investment in pandemic surveillance, multiplex respiratory testing, and rapid molecular diagnostics is sustaining long-term demand for COVID-19 detection technologies.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/49970

Key Takeaways
• Market Size (2024): USD 21.5 billion
• Forecast (2034): USD 32.7 billion
• CAGR (2025 - 2034): 4.2 %
• Leading Companies: F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Becton Dickinson and Company, Danaher Corporation, QuidelOrtho Corp., PerkinElmer Inc., Bio-Rad Laboratories Inc., and Cepheid (Danaher).
• Core Testing Technologies: RT-PCR Assays, Rapid Antigen Tests, Serology (ELISA and CLIA), and Next-Generation Sequencing (NGS).

Market Story
Even as COVID-19 transitions into an endemic stage, respiratory-panel diagnostics and multiplex molecular testing platforms continue to underpin public-health strategies. Hospitals and diagnostic labs are integrating COVID-19 testing into broader respiratory-infection surveillance, combining detection for influenza, RSV, and emerging coronavirus strains.

Technological progress-such as microfluidic cartridges, portable PCR analyzers, and AI-assisted result interpretation-is enhancing turnaround times and accuracy. Global governments and health agencies are investing in domestic manufacturing capacity to strengthen preparedness for future outbreaks.

Market Segmentation
• By Test Type: Molecular ( RT-PCR , RT-LAMP ) | Antigen Tests | Antibody Tests | Sequencing Assays

• By Mode of Testing: Laboratory-Based | Point-of-Care | At-Home (Self-Testing Kits)

• By End User: Hospitals | Diagnostic Laboratories | Public Health Agencies | Home Users

• By Region:
o North America: Largest market, driven by CDC-funded testing infrastructure and private lab expansions.
o Europe: Standardization of EU digital health certificates and surveillance initiatives.
o Asia Pacific: Fastest growth as India and China enhance domestic test kit production.
o Latin America & MEA: Ongoing WHO-supported programs for low-cost antigen testing.

Explore Full Report here: https://exactitudeconsultancy.com/reports/49970/covid-19-diagnostics-market

Recent Developments
• 2025: Roche Diagnostics launched a multi-pathogen PCR panel integrating SARS-CoV-2 and RSV detection in one run.
• 2024: Abbott expanded its BinaxNOWTM line with a next-generation AI-enabled mobile reader for home testing.
• 2023: Thermo Fisher Scientific introduced a rapid RT-PCR system suitable for airport and border screening.
• 2022: QuidelOrtho and Siemens Healthineers partnered on high-throughput antigen analyzers for hospital networks.

Expert Quote
"COVID-19 diagnostics are evolving from pandemic response to pandemic readiness. Multiplex testing and portable PCR platforms are setting new benchmarks for global disease surveillance and public-health preparedness," said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=49970

Market Drivers
1. Shift from Single-Pathogen to Multi-Pathogen Testing.
2. Government and WHO Funding for Health-Security Infrastructure.
3. Expansion of At-Home Testing and E-Health Platforms.
4. Technological Advances in Point-of-Care and Digital Diagnostics.

Forecast Outlook
Between 2025 and 2034, the COVID-19 diagnostics industry will integrate AI-based data analytics, digital certification systems, and automated sample processing into a single connected ecosystem. The future market will prioritize speed, accuracy, and supply-chain resilience to respond to any emerging pathogen threat.

Conclusion
The COVID-19 Diagnostics Market remains a strategic pillar of global public health. As healthcare systems transition to continuous surveillance models and data-driven infection control, innovations in rapid testing and connected diagnostic devices will shape the next decade of laboratory medicine.

This report is also available in the following languages : Japanese (COVID-19診断市場), Korean (코로나19 진단 시장), Chinese (新冠病毒诊断市场), French (Marché des diagnostics Covid-19), German (Covid-19-Diagnostikmarkt), and Italian (Mercato della diagnostica Covid-19), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/49970

Related Reports

Covid 19 Sample Collection Kits Market
https://exactitudeconsultancy.com/reports/49975/covid-19-sample-collection-kits-market

U.S. Covid 19 Diagnostics Market
https://exactitudeconsultancy.com/reports/50409/u-s-covid-19-diagnostics-market

Laparoscopic Devices Market
https://exactitudeconsultancy.com/reports/76126/laparoscopic-devices-market

Hydraulic Dynamometers Market
https://exactitudeconsultancy.com/reports/76127/hydraulic-dynamometers-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.